01 April | 2021
Prilenia to Present at Stifel, BMO, Needham and the European
Biotech Investor Days
[Naarden, NL, 1 April 2021] – Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that Dr Michael R. Hayden, MD, PhD Chief Executive Officer, will present at the upcoming virtual investor conferences in April:
Stifel 3rd Annual CNS Day on Thursday, April 1, 2021. A live webcast will be available at: click here
20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021.
BMO Conference Call Series: Hidden Gems in Healthcare on Wednesday, April 14, 2021. Dial in details: 800-348-8995 or +1 973-528-0026, code 548141
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check for the latest information.
About Prilenia (www.prilenia.com)
Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders. Prilenia raised $ 88.5 million thus far and is backed by a group of well-respected investors: Talisman, Forbion, Morningside and Sectoral and ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S. S.
For more information visit and follow us on twitter @prileniaTx.
Melanie Toyne-Sewell / Agnes Stephens / Siobhan Sanford
T: +44 (0) 207 457 2020